XactDose
He did speak about XactDose, albeit not to the same extent as the drug pipeline. I think he realizes the importance of signing a licensing deal for that product. It can bring in upfront cash and an ongoing royalty/revenue stream. That would be a huge catalyst for the stock. It could also be non-dilutive, and I'm sure he's cognizant of the desire to minimize dilution, particularly at the current paltry market cap.
I hope we'll see more outbound IR like this. Not sure why Alain couldn't have done a couple of interviews like that, but can't change the unfortunate past. It does indicate to me that the CRx guys will be more aggressive in marketing the story, which is a great thing.
News 
Market Data 
Discover 
